PDF(Pubmed)
Abstract：
Unlike praziquantel, artemisinin derivatives are effective against juvenile schistosome worms. We assessed the efficacy and safety of a single oral dose of artesunate plus sulfalene-pyrimethamine versus praziquantel in the treatment of Schistosoma mansoni. Seventy-three schoolchildren (aged 9-15 years) with confirmed S. mansoni infection in Rarieda, western Kenya, were randomly assigned to receive either a single oral dose of artesunate plus sulfalene-pyrimethamine (n = 39) or a single dose of praziquantel (n = 34). The cure and egg reduction rates at 4 weeks posttreatment were 69.4% (25/36) versus 80.6% (25/31) (P = 0.297) and 99.1% versus 97.5% (P = 0.607) in the artesunate plus sulfalene-pyrimethamine group versus praziquantel group, respectively. Fourteen children developed adverse events, and there were no serious adverse events. A single oral dose of artesunate plus sulfalene-pyrimethamine has efficacy comparable to that of praziquantel in the treatment of S. mansoni, but these results should be confirmed in larger randomized controlled trials.
摘要：
不像吡喹酮,青蒿素衍生物对血吸虫幼虫有效。我们评估了单次口服青蒿琥酯加磺胺嘧啶与吡喹酮治疗曼氏血吸虫的疗效和安全性。雷里达有73名确认感染曼索尼链球菌的学童(9-15岁)，肯尼亚西部,被随机分配接受单剂量的青蒿琥酯加磺胺嘧啶（n=39）或单剂量的吡喹酮（n=34）。治疗4周后，青蒿琥酯加次硫烯-乙胺嘧啶组的治愈率和减卵率分别为69.4％（25/36）和80.6％（25/31）（P=0.297）和99.1％对97.5％（P=0.607）与吡喹酮组，分别。14名儿童出现不良事件，无严重不良事件发生.单一口服剂量的青蒿琥酯加次硫烯-乙胺嘧啶在治疗曼氏链球菌方面的疗效与吡喹酮相当。但这些结果应该在更大的随机对照试验中得到证实.
